
**CLARIFICATION ANNOUNCEMENT ON BUSINESS TIMES
ARTICLE DATED 8 MARCH 2019**

The Board of Directors ("**Board**") of Singapore Medical Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Business Times article published on 8 March 2019 titled, "Healthcare plays finish well in 2018, may stay in pink of health in years ahead" which commented on the Company's recent developments.

The article states that, "In February, the group received a S\$50 million investment and the offer of a convertible loan of S\$10 million from its major shareholder CHA Healthcare Singapore."

The Company would like to clarify that the Group did not receive a S\$50 million investment from CHA Healthcare Singapore Pte Ltd ("**CHS**"), an international subsidiary of leading Korean comprehensive healthcare group CHA Health Systems. Instead, CHS had increased its stake in the Company through the purchase of existing shares from certain shareholders in a S\$50 million investment.

By Order of the Board

Dr Beng Teck Liang
Executive Director and Chief Executive Officer

8 March 2019

This Announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "Sponsor"), for compliance with the Catalist Rules. The Sponsor has not independently verified the contents of this Announcement.

This Announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Announcement, including the correctness of any of the statements or opinions made or reports contained in this Announcement.

The contact person for the Sponsor is Mr Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place #09-01, Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.